Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ifosfamide
Drug ID BADD_D01133
Description Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Indications and Usage Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
Marketing Status Prescription; Discontinued
ATC Code L01AA06
DrugBank ID DB01181
KEGG ID D00343
MeSH ID D007069
PubChem ID 3690
TTD Drug ID D02TLO
NDC Product Code 10019-925; 63323-142; 15308-0411; 10019-929; 57884-0006; 0338-3991; 0143-9530; 10019-926; 0143-9531; 10019-927; 65124-0001; 0703-3427; 0338-3993; 0703-3429
Synonyms Ifosfamide | Isofosfamide | Isophosphamide | Iphosphamide | Iso-Endoxan | Iso Endoxan | Holoxan | NSC-109,724 | NSC 109,724 | NSC109,724 | NSC-109724 | NSC 109724 | NSC109724 | Asta Z 4942
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 3778-73-2
SMILES C1CN(P(=O)(OC1)NCCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AminoaciduriaBeta-2-microglobulinP61769T580802386379; 8774570; 9261752; 1503924; 8625085; 9950195; 2060086; 1718222; 8318805; 10234592; 8070011; 10817497; 2510931; 8018491; 7787938; 8570867; 12868118; 12402147; 7510155
AnxietyAlpha-2A adrenergic receptorP08913T114487938249; 11425914
Arterial disorderElastinP15502Not Available2184650; 4077233; 10491730; 7033951; 3341387; 6489195; 2184657; 6394516; 6869203; 6616523; 9486085; 3277415; 11026649; 8562468; 6856486
Drug toleranceAlpha-2A adrenergic receptorP08913T114487938249; 11425914
GlycosuriaBeta-2-microglobulinP61769T580802386379; 8774570; 9261752; 1503924; 8625085; 9950195; 2060086; 1718222; 8318805; 10234592; 8070011; 10817497; 2510931; 8018491; 7787938; 8570867; 12868118; 12402147; 7510155
HypophosphataemiaBeta-2-microglobulinP61769T580802386379; 8774570; 9261752; 1503924; 8625085; 9950195; 2060086; 1718222; 8318805; 10234592; 8070011; 10817497; 2510931; 8018491; 7787938; 8570867; 12868118; 12402147; 7510155
Metabolic disorderS-adenosylmethionine decarboxylase proenzymeP17707T559226305362; 6121595; 6284819; 685624; 842265; 6617953; 204937
Metabolic disorderOrnithine decarboxylaseP11926T603666305362; 6121595; 6284819; 685624; 842265; 6617953; 204937
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Neoplasm progression16.16.02.0050.000139%Not Available
Pelvic neoplasm16.16.02.003; 21.07.04.003--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Renal neoplasm20.01.04.004; 16.08.03.001--Not Available
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Polyp08.01.06.010; 16.02.02.005--Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.0380.000695%
Disease recurrence08.01.03.0500.001066%Not Available
Obstruction08.01.03.023--Not Available
Psychotic disorder19.03.01.002--
Pulmonary toxicity22.01.02.007; 12.03.01.013--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Immunosuppression10.03.02.001--Not Available
Metastasis16.22.01.0010.000278%Not Available
Renal impairment20.01.03.0100.000799%Not Available
Chronic kidney disease20.01.03.0170.001066%
Bone marrow failure01.03.03.0050.002931%
Cerebral arteriosclerosis24.04.06.019; 17.08.02.008--Not Available
Thyroid cancer16.24.03.001; 05.02.05.001--Not Available
Treatment failure08.06.01.0170.000695%Not Available
Ovulation disorder21.11.02.009; 05.05.01.015--Not Available
Renal cell carcinoma16.08.02.002; 20.01.04.003--Not Available
Myocardial depression02.04.02.015--Not Available
Acute kidney injury20.01.03.0160.000799%
Foetal growth restriction18.03.01.002--
Microsomia08.01.03.056--Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages